Financial Performance and Incretin Portfolio Dominance Eli Lilly has reported its financial results for the first quarter of 2026, with total revenue surging 156% year-on-year to hit $19.8 billion. The drugmaker’s financial acceleration remains heavily anchored by its expanding incretin franchise, which logged a 90% revenue expansion during the quarter.
-
Mounjaro: The GLP-1 receptor agonist generated $8.7 billion in Q1 sales, representing a 125% year-on-year growth trajectory and solidifying its position as one of the world’s top-selling therapeutic assets.
-
Zepbound: Delivered $4.2 billion in quarterly revenue, reflecting an 80% jump compared to the identical timeline in 2025. Eli Lilly confirmed it now commands a 60.1% volume share of the total U.S. incretin analogs segment.
-
Foundayo (orforglipron): Recently cleared by the U.S. FDA as a once-daily oral pill for adult chronic weight management in patients with obesity or overweight presenting with weight-related comorbidities. In clinical evaluations, the high-dose regimen demonstrated an average weight reduction of 12.4%. Within its initial launch phase, Foundayo captured over 20,000 patients, averaging more than 1,000 new treatment starts per day, with 80% of these users being completely naive to the GLP-1 drug class. Corporate leadership plans to launch widespread direct-to-consumer (DTC) television promotional campaigns in Q3 2026 to accelerate brand differentiation.
Strategic Pipeline Diversification Beyond Metabolic Incretins While utilizing the massive cash flows generated by its metabolic segment, Eli Lilly is systematically deploying capital into multi-billion-dollar business development transactions to expand into advanced therapeutic platforms. Since January 2026, the company has closed or announced six targeted acquisitions outside the GLP-1 space:
-
Orna Therapeutics Acquisition (February): Valued at up to $2.4 billion, securing an in vivo chimeric antigen receptor (CAR) T cell therapy platform for autoimmune indications designed to bypass the clinical supply chain and manufacturing costs of ex vivo cell methods.
-
Centessa Pharmaceuticals Takeover (March): A transaction worth up to $47 per share ($38 cash plus a $9 CVR), totaling $6.3 billion, giving Lilly ownership of novel orexin receptor 2 agonist compounds developed for narcolepsy and other sleep-wake conditions.
-
CrossBridge Bio Purchase (April): A preclinical deal valued at up to $300 million for a proprietary dual-payload TROP2-targeting antibody-drug conjugate (ADC) platform utilizing site-specific linker technologies.
-
Kelonia Therapeutics Buyout (April): An oncology transaction structured with a $3.25 billion upfront cash payment and up to $7 billion in total milestones for an in vivo CAR-T delivery platform focused on multiple myeloma.
-
Ajax Therapeutics Deal (April): A transaction valued at up to $2.3 billion to absorb a Phase I next-generation Type II JAK2 inhibitor designed for myelofibrosis management.